U.S. markets closed

Revvity, Inc. (0KHE.L)

LSE - LSE Precio retrasado. Moneda en USD.
Añadir a la lista de seguimiento
104.31+0.33 (+0.32%)
Al cierre: 05:53PM BST

Revvity, Inc.

940 Winter Street
Waltham, MA 02451
United States
781 663 6900
https://www.revvity.com

Sector(es)
Industria
Empleados a tiempo completo11,000

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Dr. Prahlad R. Singh Ph.D.CEO, President & Director1.43MN/D1965
Mr. Maxwell KrakowiakSenior VP & CFO631.11kN/D1990
Mr. Tajinder S. VohraSenior Vice President of Global Operations574.08kN/D1966
Mr. Joel S. GoldbergSenior VP of Administration, General Counsel & Secretary720.74kN/D1969
Ms. Miriame VictorSenior VP & Chief Commercial Officer555.4kN/D1982
Mr. Andrew OkunVP, Chief Accounting Officer & TreasurerN/DN/D1970
Mr. Bryan A. KippSenior Vice President of Technology & LicensingN/DN/DN/D
Ms. Madhuri Hegde FACMG, Ph.D.Senior VP & Chief Scientific OfficerN/DN/DN/D
Mr. Stephen Barr WilloughbySenior VP of Investor Relations & Head of ESGN/DN/DN/D
Ms. Magali FourSenior VP & Chief People and Culture OfficerN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Gestión corporativa

La calificación ISS Governance QuickScore de Revvity, Inc. a partir del 29 de junio de 2024 es 8. Las puntuaciones principales son Auditoría: 10; Junta: 3; Derechos del accionista: 8; Compensación: 8.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.